Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2669 | Lusvertikimab (Anti-IL-7Ra / CD127) | Lusvertikimab (Anti-IL-7Ra / CD127) is a humanized monoclonal antibody targeting IL7R. It has anti-leukaemic efficacy and has the potential for B cell precursor acute lymphoblastic leukaemia (BCP-ALL) research. MW :145.64 KD. | Human IgG4SP |
| A2925 | Anti-GPR64 / ADGRG2 | Anti-GPR64 / ADGRG2 is a monoclonal antibody (mAb) against G protein-coupled receptor 64 isoform 4 (anti-GPR64) with potential anti-tumour activity. MW: 146.1. | Human IgG4SP |
| A2670 | Anti-CXCL8 / IL-8 (HuMax-IL8) | Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has a strong anti-tumour effect. MW: 144.94 KD. | Human IgG1 |
| A2926 | Lonigutamab (Anti-IGF1R / CD221) | Lonigutamab (hz208F2-4) is a humanised monoclonal antibody against the insulin-like growth factor-1 receptor (IGF-1R) with the potential to treat thyroid eye disease (TED). MW: 146.26 KD. | Human IgG1 |
| A2671 | Anti-Lewis Y (MB 311) | Anti-Lewis Y (MB 311) is a fully humanised monoclonal antibody recognising the tumour-associated antigen Lewis Y. It represents an attractive target for cancer immunotherapy and can be used in treatment of breast cancer. MW 146.38 KD. | Human IgG1 |
| A2927 | Losatuxizumab (Anti-ERBB1 / EGFR / HER1) | Losatuxizumab (ABT-806) is a human monoclonal antibody against EGFR with anti-tumour activity. MW: 144.8 KD. | Human IgG1 |
| A2672 | Anti-MAGEA3 | Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW: 145.56 KD. | Human IgG1 |
| A2928 | Anti-Hepcidin / HAMP (anti_Hepsin) | Anti-Hepcidin / HAMP is a monoclonal antibody (mAb) that neutralising hepcidin and results in transferrin-mediated iron transport. MW: 142.68. | Human IgG1 |
| A2673 | Anetumab (Anti-Mesothelin) | Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD. | Human IgG1 |
| A2929 | Anti-KID3 | Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD. | Human IgG1 |
| A2674 | Oregovomab (Anti-MUC16) | Oregovomab (Anti-MUC16) is a humanised monoclonal antibody that targets MUC16. It can be used in treatment of ovarian, pancreatic, breast, and lung cancers. MW 150 KD. | Human IgG1 |
| A2930 | Anti-HGF / SF (TAK-701) | Anti-HGF / SF (TAK-701) is a humanised monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. It reverses gefitinib resistance in non-small-cell lung cancer. MW: 145.04 KD. | Human IgG1 |
| A2675 | Sofituzumab (Anti-MUC16) | Sofituzumab (Anti-MUC16) is a humanised recombinant V-kappa antibody targeting MUC16. It can be used for the research of ovarian cancer. MW 144.7 KD. | Human IgG1 |
| A2676 | Landogrozumab (Anti-GDF8 / Myostatin) | Landogrozumab (Anti-GDF8 / Myostatin) is a humanised monoclonal antibody targeting myostatin. It effectively improves muscle volume, hand grip strength and function and can be used for the research of muscle wasting disease. MW: 150 KD. | Human IgG4SP |
| A2932 | Anti-HGFR / c-Met (SAIT301) | Anti-HGFR / c-Met (SAIT301) is a humanised monoclonal antibody targeting the alpha chain of the extracellular domain of the human hepatocyte growth factor receptor (HGFR or c-Met) with potential antineoplastic activity. MW: 146.0 KD. | Human IgG1 |
| A2677 | Trevogrumab (Anti-GDF8 / Myostatin) | Trevogrumab (Anti-GDF8 / Myostatin) is a monoclonal antibody targeting GDF8. It is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake. MW: 150 KD. | Human IgG4SP |
| A2933 | Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) | Anti-Amyloid Beta (Merck anti-Amyloid beta 19.3) is a human monoclonal antibody targeting Beta Amyloid with the potential to treat Alzheimer’s disease. MW: 145.22 KD. | Human IgG1 |
| A2678 | Fulranumab (Anti-NGF / bNGF) | Fulranumab (Anti-NGF / bNGF) is a human IgG2 monoclonal antibody targeting nerve growth factor (NGF). It can be used for the research of pain. MW: 145.37 KD. | Human IgG2SA |
| A2679 | Tanezumab (Anti-NGF / bNGF) | Tanezumab (Anti-NGF / bNGF) is a human IgG2 monoclonal antibody targeting nerve growth factor (NGF). It can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. MW :150 KD. | Human IgG1 |
| A2935 | Mirzotamab (Anti-B7-H3 / CD276) | Mirzotamab (Anti-B7-H3 / CD276) is a human IgG1κ monoclonal antibody targeting CD276/B7-H3. Mirzotamab is used to produce Mirzotamab clezutoclax antibody drug conjugate (ADC). MW: 144.86 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.